Ngenbio Signs MOU with Autotelic Bio for NGS-Based Companion Diagnostic Technology Development

[Asia Economy Reporter Minji Lee] Precision diagnostic platform specialist NGENBIO announced on the 11th that it has signed a Memorandum of Understanding (MOU) with innovative drug research and development company Autotelic Bio to develop next-generation sequencing (NGS)-based companion diagnostic technology.

Autotelic Bio is an innovative drug R&D company based on oligonucleotides, currently developing ATB-301 (TGF-β2 inhibition & T-Cell activation; Immuno-Target Dual Action Onco-therapeutic), an immune-targeted dual-function anticancer drug, and plans to conduct a Phase 1b clinical trial in the first quarter of this year.

Through this MOU, both companies plan to develop biomarker and genomic NGS diagnostic panels for ATB-301 companion diagnostics to apply in selecting clinical trial patients.

Taehun Kim, CEO of Autotelic Bio, explained, “We expect to discover new anticancer biomarkers and improve the therapeutic efficacy of immuno-oncology drugs through joint development of companion diagnostic technology with NGENBIO.”

Chaechul Choi, CEO of NGENBIO, added, “To ensure the success of the ATB-301 drug development project, we will make full use of commercially validated NGS-based precision diagnostic products and analysis software,” and said, “We will do our best to cooperate so that both companies can achieve a win-win outcome.”

This content was produced with the assistance of AI translation services.